AL
ALC.US Alcon AG
- Market cap
- USD 35.6B
- P/E
- 54.1x
- P/B
- 1.59x
- ROE
- 2.7%
- Dividend yield
- 0.47%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALC.US undervalued?
Graham numberALC.US trades 95.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alcon AG fundamental analysis
No fundamental analysis for Alcon AG yet.
Alcon AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alcon AG
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, Len…
Full company profileAlcon AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alcon AG annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.60B | 6.79B | 7.15B | 7.51B | 6.83B | 8.29B | 8.72B | 9.46B | 9.91B | 10.4B | 11.0B |
| Gross Profit | 3.11B | 3.20B | 3.19B | 3.66B | 2.94B | 4.65B | 4.75B | 5.25B | 5.51B | 5.75B | 6.39B |
| Operating Income | 10.0M | -77.0M | -248M | -187M | -482M | 580M | 672M | 1.04B | 1.41B | 1.36B | 1.07B |
| EBITDA | 1.17B | 1.20B | 1.35B | 1.22B | 1.08B | 1.76B | 1.74B | 2.24B | 2.68B | 2.50B | 2.72B |
| Net Income | -170M | 256M | -227M | -656M | -531M | 376M | 335M | 974M | 1.02B | 980M | 594M |
| EPS | -0.35 | 0.52 | -0.46 | -1.34 | -1.09 | 0.76 | 0.68 | 1.96 | 2.05 | 1.98 | 1.23 |
| Balance Sheet | |||||||||||
| Total Assets | 27.7B | 27.4B | 27.1B | 27.7B | 27.6B | 28.0B | 29.2B | 29.6B | 30.3B | 31.6B | 31.4B |
| Total Liabilities | 4.73B | 4.36B | 4.42B | 8.35B | 8.78B | 8.74B | 9.53B | 8.99B | 8.79B | 9.52B | 9.63B |
| Shareholders' Equity | 23.0B | 23.0B | 22.6B | 19.3B | 18.8B | 19.3B | 19.7B | 20.6B | 21.6B | 22.0B | 21.7B |
| Cash & Short-term Investments | 162M | 172M | 258M | 855M | 1.57B | 1.58B | 980M | 1.10B | 1.83B | 1.61B | 1.81B |
| Total Debt | 249M | 149M | 136M | 3.80B | 4.50B | 4.48B | 5.07B | 5.14B | 5.14B | 5.25B | 5.33B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.25B | 1.22B | 1.14B | 920M | 823M | 1.35B | 1.22B | 1.39B | 2.08B | 2.27B | 2.24B |
| Capital Expenditure | 506M | 496M | 712M | 676M | 567M | 1.18B | 745M | 851M | 670M | 663M | 508M |
| Free Cash Flow | 739M | 722M | 428M | 244M | 256M | 165M | 472M | 537M | 1.41B | 1.61B | 1.73B |
| Ratios | |||||||||||
| ROE | -0.7% | 1.1% | -1.0% | -3.4% | -2.8% | 2.0% | 1.7% | 4.7% | 4.7% | 4.4% | 2.7% |
| ROA | -0.6% | 0.9% | -0.8% | -2.4% | -1.9% | 1.3% | 1.1% | 3.3% | 3.4% | 3.1% | 1.9% |
| Net Profit Margin | -2.6% | 3.8% | -3.2% | -8.7% | -7.8% | 4.5% | 3.8% | 10.3% | 10.3% | 9.4% | 5.4% |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.20x | 0.24x | 0.23x | 0.26x | 0.25x | 0.24x | 0.24x | 0.25x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alcon AG dividends
- Dividend yield
- 0.47%
- Forward dividend
- 0.36 USD
- Payout ratio
- 16.9%
- Ex-dividend date
- May 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 166M | 0.33 | 16.9% |
| 2024 | USD 130M | 0.26 | 12.8% |
| 2023 | USD 116M | 0.23 | 11.9% |
| 2022 | USD 100M | 0.20 | 29.9% |
| 2021 | USD 54.0M | 0.11 | 14.4% |
| 2020 | USD 54.0M | 0.11 | - |
| 2019 | USD 54.0M | 0.11 | - |
| 2018 | USD 54.0M | 0.11 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Alcon AG
- Insiders 0.85%
- Institutions 63.11%
- Public & others 36.04%
- Shares outstanding 480M
- Free float 479M
Top funds holding ALC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Total Intl Stock Index Inv | 7.20M | 1.49% | +0.29% | Sep 2026 |
| Vanguard Developed Markets Index Admiral | 4.75M | 0.98% | -0.33% | Sep 2026 |
| iShares Core MSCI EAFE ETF | 3.74M | 0.77% | 0.00% | Oct 2026 |
| Allspring Special Mid Cap Value Inst | 3.28M | 0.68% | 0.00% | Sep 2026 |
| UBS(CH)IF Equities CH All NSL I-B-acc | 3.08M | 0.64% | -0.45% | Oct 2026 |
| Vanguard Windsor II Inv | 2.92M | 0.60% | 0.00% | Sep 2026 |
| Equities CH ESG All Index A-acc | 2.66M | 0.55% | +215.36% | Sep 2026 |
| SWC (CH) IEF Switzerland Ttl Resp GT CHF | 2.52M | 0.52% | +1.23% | Sep 2026 |
| MFS International Intrinsic Equity A | 2.42M | 0.50% | 0.00% | Sep 2026 |
| Vanguard International Growth Inv | 2.22M | 0.46% | -2.90% | Sep 2026 |
| Fidelity Series Large Cap Stock | 2.08M | 0.43% | 0.00% | Sep 2026 |
| Fidelity International Index | 1.93M | 0.40% | -1.45% | Sep 2026 |
| UBS (CH) IF Eqs Switz Pasv All II I-B | 1.92M | 0.40% | +0.61% | Sep 2026 |
| UBS (CH) IF - Eq CH All ESG NSL I-X-acc | 1.81M | 0.37% | -0.96% | Aug 2026 |
| iShares MSCI EAFE ETF | 1.78M | 0.37% | 0.00% | Oct 2026 |
| iShares Core SPI® ETF (CH) | 1.62M | 0.34% | +0.78% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.61M | 0.33% | 0.00% | Sep 2026 |
| Schroder ISF US Large Cap A Dis $ AV | 1.60M | 0.33% | -1.54% | Sep 2026 |
| SWC (CH) IEF CH Ttl (II) DA CHF | 1.59M | 0.33% | -0.25% | Sep 2026 |
| Eq CH Leader Index A-acc | 1.55M | 0.32% | +1.22% | Sep 2026 |
Top institutions holding ALC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 14.7M | 3.05% | -0.82% | Jun 2026 |
| Bank of New York Mellon Corp | 13.1M | 2.70% | -16.67% | Jun 2026 |
| NORGES BANK | 11.0M | 2.27% | -8.93% | Jun 2026 |
| Amvescap Plc. | 10.4M | 2.15% | +2,786.30% | Jun 2026 |
| Ako Capital Llp | 9.68M | 2.00% | +3.84% | Jun 2026 |
| Aristotle Capital Management LLC | 9.15M | 1.89% | -5.82% | Jun 2026 |
| Zurcher Kantonalbank | 7.92M | 1.64% | -1.34% | Jun 2026 |
| FMR Inc | 7.66M | 1.59% | -38.34% | Jun 2026 |
| UBS Group AG | 7.16M | 1.48% | +20.65% | Jun 2026 |
| Amundi | 6.64M | 1.37% | +16.28% | Jun 2026 |
| Select Equity Group LP | 5.77M | 1.19% | +1.59% | Jun 2026 |
| Vontobel Holding Ltd. | 5.64M | 1.17% | +3.30% | Jun 2026 |
| Pictet Asset Manangement SA | 5.53M | 1.14% | +11.15% | Jun 2026 |
| Deutsche Bank AG | 5.35M | 1.11% | +7.36% | Jun 2026 |
| The Goldman Sachs Group Inc | 4.68M | 0.97% | -19.70% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 4.32M | 0.89% | -0.90% | Jun 2026 |
| Allspring Global Investments Holdings, LLC | 4.10M | 0.85% | -0.68% | Jun 2026 |
| Royal Bank of Canada | 4.02M | 0.83% | -3.43% | Jun 2026 |
| Legal & General Group PLC | 3.81M | 0.79% | -3.50% | Jun 2026 |
| Troy Asset Management Limited | 3.80M | 0.79% | +27.21% | Jun 2026 |
Alcon AG company profile
- Company name
- Alcon AG
- Ticker
- ALC.US
- ISIN
- CH0432492467
- Exchange
- USA Stocks
- Listed since
- Apr 9, 2019
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 25,942
- Fiscal year end
- December
- Address
- Chemin de Blandonnet 8, Geneva, Switzerland, 1214
- Phone
- 41 589 112 110
- Website
- alcon.com
About Alcon AG
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. In addition it also develops and commercializes therapies for chronic eye diseases, focusing on encapsulated cell therapy platforms for ocular conditions. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Alcon AG management
10- Mr. David J. EndicottCEO & Director · born 1965
- Mr. Timothy C. StonesiferSenior VP & CFO · born 1967
- Mr. Ian BellSenior VP & COO · born 1971
- Margaret BuckleyChief Accounting Officer
- Dr. Franck Leveiller Ph.D.SVP of Global Research & Development and Chief Scientific Officer
- Mr. Muru MurugappanSenior VP and Chief Information & Transformation Officer
- Mr. Daniel CravensVice President of Investor Relations
- Mr. Royce R. Bedward J.D.Senior VP, General Counsel & Corporate Secretary · born 1966
- Ms. Kimberly MartinSenior VP and Chief HR & Corporate Communications · born 1975
- Mr. Leon Sergio Duplan FraustroSenior VP & President of Americas · born 1968